Bug-Busting Grows Sophisticated

Credit: William Jacobs, Albert Einstein College of MedicineTuberculosis bacterium The battles that scientists wage against bacteria and viruses resemble chess matches between grandmasters and supercomputers. Highly intelligent people are pitted against entities that aren't conscious but that nevertheless hold two big advantages. Populated by hosts of individually sensitive microchips or microorganisms, these entities can react with lightning speed. And tutored intensively by computer programmers

Written byDouglas Steinberg
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

Credit: William Jacobs, Albert Einstein College of Medicine

Tuberculosis bacterium
The battles that scientists wage against bacteria and viruses resemble chess matches between grandmasters and supercomputers. Highly intelligent people are pitted against entities that aren't conscious but that nevertheless hold two big advantages. Populated by hosts of individually sensitive microchips or microorganisms, these entities can react with lightning speed. And tutored intensively by computer programmers or the demands of natural selection, they can respond devastatingly to opponents' moves.

Just as IBM's Deep Blue beat then-world chess champ Garry Kasparov in 1997, pathogens such as HIV and antibiotic-resistant bacteria have lately been prevailing against the best-laid plans to eradicate them. In response, scientists have been turning to the newest molecular, biochemical, and genetic techniques. This shift was evident at a Nov. 9 symposium at Rockefeller University in New York titled "Infectious Disease and Antibiotic Resistance in the Postgenomic Era." Since its founding ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies